Arcturus Therapeutics (ARCT) Reports Q4 Loss of $1.03

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.03). Revenue for the quarter came in at $7.2 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Lam Research (LRCX) PT Raised to $500 at Cantor Fitzgerald: Gaining Most Share in Group
• NN Inc. expands Nvidia data center liquid cooling supply contracts
• Honeywell Aerospace begins trading on Nasdaq after HON spin-off